世界のがん診断市場予測(~2026年):製品別(消耗品(抗体、プローブ)、器具(病理学器具、画像用器具、生検)、技術別(IVD検査)、用途別(乳がん、肺がん)、エンドユーザー別(病院)

【英語タイトル】Cancer Diagnostics Market by Product (Consumables (Anitibodies, Probes), Instruments (Pathology Instruments, Imaging Instruments, Biopsy), Technology (IVD Testing), Application (Breast Cancer, Lung Cancer), End User (Hospitals)- Global Forecasts to 2026

MarketsandMarketsが出版した調査資料(MD3480)・商品コード:MD3480
・発行会社(調査会社):MarketsandMarkets
・発行日:2021年4月30日
・ページ数:282
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥732,600見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥984,200見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥1,206,200見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
マーケッツアンドマーケッツ社は世界のがん診断市場規模が2021年172億ドルから2026年266億ドルまで、年平均11.5%成長すると予想しています。本調査レポートでは、がん診断の世界市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別(消耗品、器具)分析、技術別(IVD検査、画像技術、生検)分析、用途別(乳がん、肺がん、結腸直腸がん、黒色腫、その他がん)分析、エンドユーザー別(病院、診断ラボ)分析、地域別分析、競争状況、企業情報などを掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界のがん診断市場規模:製品別(消耗品、器具)
・世界のがん診断市場規模:技術別(IVD検査、画像技術、生検)
・世界のがん診断市場規模:用途別(乳がん、肺がん、結腸直腸がん、黒色腫、その他がん)
・世界のがん診断市場規模:エンドユーザー別(病院、診断ラボ)
・世界のがん診断市場規模:地域別
・競争状況
・企業情報
❖ レポートの概要 ❖

“The global cancer diagnostics market size is projected to reach USD 26.6 billion by 2026 from USD 17.2 billion in 2021, at a CAGR of 11.5% from 2021 to 2026.”
Growth in this market is driven by the rising prevalence of cancer, and growing initiatives undertaken by government bodies to create awareness about cancer, the increasing number of private diagnostic centers.

“Consumables segment to witness the highest growth during the forecast period.”
Based on the product, the cancer diagnostics market is segmented into consumables and instruments. The consumables segment is projected to grow at the highest CAGR during the forecast period. high prevalence of cancer, number of reagent rental agreements, and the growing application of innovative technologies and methodologies are the major factor supporting the growth of this segment.

“Breast cancer segment to register the highest growth in the cancer diagnostics market during the forecast period.”
Based on the application, the cancer diagnostics market is segmented into breast cancer, lung cancer, colorectal cancer, melanoma, and other cancer. The breast cancer segment is projected to witness the highest growth in the cancer diagnostics market during the forecast period. The increasing incidence of cancer and technological advancement are the major factors supporting the growth of this segment.

“Asia Pacific is estimated to register the highest CAGR during the forecast period.”
In this report, the cancer diagnostics market is segmented into four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). The market in Asia Pacific is projected to register the highest growth rate during the forecast period. The growth in this market is primarily driven by The increasing incidence of cancer, increasing number of patients visiting hospitals, and growing awareness regarding early diagnosis.

Breakdown of supply-side primary interviews, by company type, designation, and region:
• By Company Type: Tier 1 (32%) , Tier 2 (44%), and Tier 3 (24%)
• By Designation: C-level (30%), Director-level (34%), and Others (36%)
• By Region: North America (40%), Europe (28%), AsiaPacific (20%), and Rest of the World(12%)

List of Companies Profiled in the Report:
• GE Healthcare (US)
• Abbott Laboratories (US)
• Hologic Inc. (US)
• Agilent Technologies Inc.(US)
• Roche Diagnostics (Switzerland)
• FUJIFILM Corporation (Japan)
• Danaher Corporation (US)
• DiaSorin S.P.A. (Italy)
• Myriad Genetics Inc. (US)
• Siemens Healthineers AG (Germany)
• BD (US)
• bioMérieux SA (France)
• Bio-Rad Laboratories (US)
• Cancer Diagnostics Inc. (US)
• Vela Diagnostics (Singapore)
• Roche Diagnostics (Switzerland)
• AMOY Diagnostics CO. LTD. (China)
• Quidel Corporation (US)
• Bio SB (US)
• Biocartis NV (Belgium)
• Exact Science (US)

Research Coverage:
This report studies the cancer diagnostics market based on product, technology, application, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total cancer diagnostics market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on cancer diagnostics products offered by the top 23 players in the cancer diagnostics market. The report analyzes the cancer diagnostics market by product, technology, application, end user, and region.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various securement devices across key geographic regions.
• Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the cancer diagnostics market
• Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the cancer diagnostics market

❖ レポートの目次 ❖

1 INTRODUCTION 39
1.1 OBJECTIVES OF THE STUDY 39
1.2 MARKET DEFINITION 39
1.2.1 INCLUSIONS AND EXCLUSIONS OF THE STUDY 40
1.3 MARKET SCOPE 40
1.3.1 MARKET SEGMENTATION 40
1.3.2 YEARS CONSIDERED FOR THE STUDY 41
1.4 CURRENCY 41
1.5 LIMITATIONS 41
1.6 MARKET STAKEHOLDERS 41
1.7 SUMMARY OF CHANGES 42
2 RESEARCH METHODOLOGY 43
2.1 RESEARCH DATA 43
FIGURE 1 RESEARCH DESIGN 43
2.1.1 SECONDARY DATA 44
2.1.1.1 Secondary sources 45
2.1.2 PRIMARY DATA 45
FIGURE 2 PRIMARY SOURCES 45
2.1.2.1 Key data from primary sources 46
2.1.2.2 Key industry insights 47
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 47
2.2 MARKET SIZE ESTIMATION 48
FIGURE 4 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 48
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 49
FIGURE 6 TOP-DOWN APPROACH 50
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 51
FIGURE 7 DATA TRIANGULATION METHODOLOGY 51
2.4 MARKET SHARE ANALYSIS 52
2.5 ASSUMPTIONS FOR THE STUDY 52
2.6 COVID-19 HEALTH ASSESSMENT 53
2.7 COVID-19 ECONOMIC ASSESSMENT 53
2.8 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 53
FIGURE 8 CRITERIA IMPACTING THE GLOBAL ECONOMY 54
FIGURE 9 RECOVERY SCENARIO OF THE GLOBAL ECONOMY 55

3 EXECUTIVE SUMMARY 56
FIGURE 10 CANCER DIAGNOSTICS MARKET, BY PRODUCT,
2021 VS. 2026 (USD BILLION) 56
FIGURE 11 CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,
2021 VS. 2026 (USD BILLION) 57
FIGURE 12 CANCER DIAGNOSTICS MARKET, BY APPLICATION,
2021 VS. 2026 (USD BILLION) 57
FIGURE 13 CANCER DIAGNOSTICS MARKET, BY END USER,
2021 VS. 2026 (USD BILLION) 58
FIGURE 14 CANCER DIAGNOSTICS MARKET, BY REGION, 2021 VS. 2026 (USD BILLION) 58
4 PREMIUM INSIGHTS 60
4.1 CANCER DIAGNOSTICS MARKET OVERVIEW 60
FIGURE 15 INCREASING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH
DURING THE FORECAST PERIOD 60
4.2 CANCER DIAGNOSTICS MARKET, BY PRODUCT 61
FIGURE 16 INSTRUMENTS SEGMENT ACCOUNTED FOR THE LARGEST
MARKET SHARE IN 2020 61
4.3 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY PRODUCT AND COUNTRY, 2020 61
FIGURE 17 US DOMINATED THE NORTH AMERICAN CANCER DIAGNOSTICS
MARKET IN 2020 61
4.4 GEOGRAPHICAL SNAPSHOT OF THE CANCER DIAGNOSTICS MARKET 62
FIGURE 18 CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD 62
5 MARKET OVERVIEW 63
5.1 INTRODUCTION 63
5.2 MARKET DYNAMICS 63
FIGURE 19 CANCER DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 63
5.2.1 DRIVERS 64
5.2.1.1 Increasing incidence of cancer 64
TABLE 1 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS.
2030 VS. 2040 (MILLION) 64
TABLE 2 PROJECTED INCREASE IN THE GLOBAL NUMBER OF CANCER PATIENTS,
2015 VS. 2018 VS. 2035 65
5.2.1.2 Growth in the number of private diagnostic centers 65
5.2.1.3 Availability of reimbursement 65
5.2.2 RESTRAINTS 66
5.2.2.1 High capital investments and low cost-benefit ratio for biomarkers 66
5.2.2.2 High cost of diagnostic imaging systems 66
5.2.2.3 Product recalls and failure 67
5.2.3 OPPORTUNITIES 67
5.2.3.1 Growing focus on personalized medicine 67
FIGURE 20 RISING NUMBER OF PERSONALIZED MEDICINES, 2008–2020 68
5.2.3.2 Companion diagnostics 68
5.2.3.3 Recommendations for cancer screening 68
5.2.3.4 Emerging countries 69
5.2.4 CHALLENGES 69
5.2.4.1 Increasing adoption of refurbished diagnostic imaging systems 69
5.2.4.2 Lack of skilled professionals 69
TABLE 3 NUMBER OF PATHOLOGISTS PER 10,000 POPULATION, BY COUNTRY, 2018 69
5.2.4.3 Inadequate infrastructure and low awareness in middle- and
low-income countries 70
5.2.5 TRENDS 70
5.2.5.1 Rental agreements 70
5.3 COVID-19 IMPACT ANALYSIS 70
5.4 VALUE CHAIN ANALYSIS 71
FIGURE 21 MAJOR VALUE IS ADDED DURING THE MANUFACTURING &
ASSEMBLY PHASES 71
5.5 SUPPLY CHAIN ANALYSIS 72
FIGURE 22 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES 73
5.6 PORTER’S FIVE FORCES ANALYSIS 73
5.6.1 THREAT FROM NEW ENTRANTS 73
5.6.2 INTENSITY OF COMPETITIVE RIVALRY 73
5.6.3 BARGAINING POWER OF BUYERS 74
5.6.4 BARGAINING POWER OF SUPPLIERS 74
5.6.5 THREAT FROM SUBSTITUTES 74
5.7 TECHNOLOGY ANALYSIS 74
5.8 REGULATORY LANDSCAPE 74
FIGURE 23 510(K) APPROVAL PROCESS 75
5.9 PATENT ANALYSIS 76
5.10 TRADE ANALYSIS 76
5.10.1 TRADE ANALYSIS FOR MAMMOGRAPHY SYSTEMS 76
TABLE 4 IMPORT DATA FOR MAMMOGRAPHY SYSTEMS, BY COUNTRY,
2016—2020 (USD MILLION) 76
TABLE 5 EXPORT DATA FOR MAMMOGRAPHY SYSTEMS, BY COUNTRY,
2016—2020 (USD MILLION) 77
5.10.2 TRADE ANALYSIS FOR MAGNETIC RESONANCE IMAGING (MRI) SYSTEMS 77
TABLE 6 IMPORT DATA FOR MRI SYSTEMS, BY COUNTRY, 2016—2020 (USD MILLION) 77
TABLE 7 EXPORT DATA FOR MRI SYSTEMS, BY COUNTRY, 2016—2020 (USD MILLION) 78
5.11 PRICING ANALYSIS 78
TABLE 8 PRICES OF CANCER DIAGNOSTIC PRODUCTS 78
5.12 ECOSYSTEM ANALYSIS: CANCER DIAGNOSTICS MARKET 79
5.12.1 ROLE IN ECOSYSTEM 79
5.13 YCC SHIFT 80

6 CANCER DIAGNOSTICS MARKET, BY PRODUCT 81
6.1 INTRODUCTION 82
TABLE 9 CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 82
6.2 CONSUMABLES 82
TABLE 10 CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2019–2026 (USD MILLION) 82
TABLE 11 CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY REGION,
2019–2026 (USD MILLION) 83
6.2.1 ANTIBODIES 83
6.2.1.1 Antibodies accounted for the largest share of the cancer diagnostic consumables market in 2020 83
TABLE 12 CANCER DIAGNOSTICS MARKET FOR ANTIBODIES, BY REGION,
2019–2026 (USD MILLION) 84
6.2.2 KITS & REAGENTS 84
6.2.2.1 Use of kits is increasing among end users owing to their ease of use 84
TABLE 13 CANCER DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY REGION,
2019–2026 (USD MILLION) 84
6.2.3 PROBES 85
6.2.3.1 Abbott and Agilent Technologies are some of the leading players operating in this market segment 85
TABLE 14 CANCER DIAGNOSTICS MARKET FOR PROBES, BY REGION,
2019–2026 (USD MILLION) 85
6.2.4 OTHER CONSUMABLES 85
TABLE 15 CANCER DIAGNOSTICS MARKET FOR OTHER CONSUMABLES, BY REGION, 2019–2026 (USD MILLION) 85
6.3 INSTRUMENTS 86
TABLE 16 CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE,
2019–2026 (USD MILLION) 86
TABLE 17 CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION,
2019–2026 (USD MILLION) 86
6.3.1 PATHOLOGY-BASED INSTRUMENTS 86
TABLE 18 CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS,
BY TYPE, 2019–2026 (USD MILLION) 87
TABLE 19 CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS,
BY REGION, 2019–2026 (USD MILLION) 87
6.3.1.1 Slide staining systems 87
6.3.1.1.1 Slide staining systems accounted for the largest share of the pathology-based instruments market 87
TABLE 20 CANCER DIAGNOSTICS MARKET FOR SLIDE STAINING SYSTEMS, BY REGION, 2019–2026 (USD MILLION) 88
6.3.1.2 Tissue processing systems 88
6.3.1.2.1 Tissue processing systems are used for the automatic processing of tissue samples 88
TABLE 21 CANCER DIAGNOSTICS MARKET FOR TISSUE PROCESSING SYSTEMS,
BY REGION, 2019–2026 (USD MILLION) 89

6.3.1.3 Cell processors 89
6.3.1.3.1 Cell processors are used to remove unwanted matter from cytology samples 89
TABLE 22 CANCER DIAGNOSTICS MARKET FOR CELL PROCESSORS, BY REGION,
2019–2026 (USD MILLION) 89
6.3.1.4 PCR instruments 90
6.3.1.4.1 Cost-effectiveness of PCR is driving the growth of this market segment 90
TABLE 23 CANCER DIAGNOSTICS MARKET FOR PCR INSTRUMENTS, BY REGION,
2019–2026 (USD MILLION) 90
6.3.1.5 NGS instruments 90
6.3.1.5.1 NGS is an emerging technology for cancer diagnostics 90
TABLE 24 CANCER DIAGNOSTICS MARKET FOR NGS INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION) 90
6.3.1.6 Microarrays 91
6.3.1.6.1 DNA microarrays are useful for the determination of primary sites in metastatic carcinomas 91
TABLE 25 CANCER DIAGNOSTICS MARKET FOR MICROARRAYS, BY REGION,
2019–2026 (USD MILLION) 91
6.3.1.7 Other pathology-based instruments 91
TABLE 26 CANCER DIAGNOSTICS MARKET FOR OTHER PATHOLOGY-BASED INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION) 92
6.3.2 IMAGING INSTRUMENTS 92
TABLE 27 CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 92
TABLE 28 CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION) 93
6.3.2.1 CT systems 93
6.3.2.1.1 Technological advancements in CT to drive the growth of this market segment 93
TABLE 29 CANCER DIAGNOSTICS MARKET FOR CT SYSTEMS, BY REGION,
2019–2026 (USD MILLION) 93
6.3.2.2 Ultrasound systems 94
6.3.2.2.1 Increasing incidence of cancer to drive the growth of this market segment 94
TABLE 30 CANCER DIAGNOSTICS MARKET FOR ULTRASOUND SYSTEMS, BY REGION, 2019–2026 (USD MILLION) 94
6.3.2.3 MRI systems 94
6.3.2.3.1 Use of MRI in cancer diagnostics has increased
over the years 94
TABLE 31 CANCER DIAGNOSTICS MARKET FOR MRI SYSTEMS, BY REGION,
2019–2026 (USD MILLION) 94
6.3.2.4 Mammography systems 95
6.3.2.4.1 Increasing incidence of breast cancer to drive the growth of this market segment 95
TABLE 32 CANCER DIAGNOSTICS MARKET FOR MAMMOGRAPHY SYSTEMS, BY REGION, 2019–2026 (USD MILLION) 95
6.3.2.5 Nuclear imaging systems 95
6.3.2.5.1 Technological advancements in nuclear imaging systems to drive the growth of this market segment 95
TABLE 33 CANCER DIAGNOSTICS MARKET FOR NUCLEAR IMAGING SYSTEMS,
BY REGION, 2019–2026 (USD MILLION) 95
6.3.3 BIOPSY INSTRUMENTS 96
6.3.3.1 Increasing prevalence of cancer to drive the growth of this
market segment 96
TABLE 34 CANCER DIAGNOSTICS MARKET FOR BIOPSY INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION) 96
7 CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 97
7.1 INTRODUCTION 98
TABLE 35 CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 98
7.2 IVD TESTING 98
TABLE 36 CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE,
2019–2026 (USD MILLION) 98
TABLE 37 CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY REGION,
2019–2026 (USD MILLION) 99
7.2.1 POLYMERASE CHAIN REACTION 99
7.2.1.1 Physicians prefer PCR-based diagnostic tests as they provide simple representations of genomic data 99
TABLE 38 CANCER DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION,
BY REGION, 2019–2026 (USD MILLION) 100
7.2.2 IN SITU HYBRIDIZATION 100
7.2.2.1 ISH is used for the identification of specific mRNA species within sample cells 100
TABLE 39 CANCER DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2019–2026 (USD MILLION) 101
7.2.3 IMMUNOHISTOCHEMISTRY 101
7.2.3.1 Increasing use of IHC tests for cancer diagnostics to boost
the market growth 101
TABLE 40 CANCER DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2019–2020 (USD MILLION) 102
7.2.4 NEXT-GENERATION SEQUENCING 102
7.2.4.1 NGS dominated the IVD testing market in 2020 102
TABLE 41 CANCER DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING,
BY REGION, 2019–2026 (USD MILLION) 103
7.2.5 IMMUNOASSAY 103
7.2.5.1 Immunoassay segment accounted for the second-largest share of the cancer diagnostics market for IVD testing 103
TABLE 42 CANCER DIAGNOSTICS MARKET FOR IMMUNOASSAY, BY REGION,
2019–2026 (USD MILLION) 104
7.2.6 MICROARRAY 104
7.2.6.1 Cost-effectiveness of the microarray technology to
support market growth 104
TABLE 43 CANCER DIAGNOSTICS MARKET FOR MICROARRAY, BY REGION,
2019–2026 (USD MILLION) 105
7.2.7 FLOW CYTOMETRY 105
7.2.7.1 Flow cytometry tools help to detect the number of chromosomes to determine the malignancy of a tumor 105
TABLE 44 CANCER DIAGNOSTICS MARKET FOR FLOW CYTOMETRY, BY REGION,
2019–2026 (USD MILLION) 106
7.2.8 OTHER IVD TECHNOLOGIES 106
TABLE 45 CANCER DIAGNOSTICS MARKET FOR OTHER IVD TECHNOLOGIES, BY REGION, 2019–2026 (USD MILLION) 106
7.3 IMAGING TECHNOLOGIES 107
TABLE 46 CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION) 107
TABLE 47 CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY REGION, 2019–2026 (USD MILLION) 107
7.3.1 MAGNETIC RESONANCE IMAGING 108
7.3.1.1 Technological advancements to boost the growth of the MRI market 108
TABLE 48 CANCER DIAGNOSTICS MARKET FOR MAGNETIC RESONANCE IMAGING,
BY REGION, 2019–2026 (USD MILLION) 108
7.3.2 COMPUTED TOMOGRAPHY 109
7.3.2.1 CT is a widely used technique in cancer diagnostics 109
TABLE 49 CANCER DIAGNOSTICS MARKET FOR COMPUTED TOMOGRAPHY, BY REGION, 2019–2026 (USD MILLION) 109
7.3.3 NUCLEAR IMAGING 110
7.3.3.1 PET is a widely used nuclear imaging technique in cancer diagnostics 110
TABLE 50 CANCER DIAGNOSTICS MARKET FOR NUCLEAR IMAGING, BY REGION,
2019–2026 (USD MILLION) 110
7.3.4 MAMMOGRAPHY 110
7.3.4.1 Increasing government initiatives for breast cancer screening to drive the growth of this market segment 110
TABLE 51 CANCER DIAGNOSTICS MARKET FOR MAMMOGRAPHY, BY REGION,
2019–2026 (USD MILLION) 111
7.3.5 ULTRASOUND 111
7.3.5.1 Adoption of POC ultrasound for diagnostic purposes to support market growth 111
TABLE 52 CANCER DIAGNOSTICS MARKET FOR ULTRASOUND, BY REGION,
2019–2026 (USD MILLION) 112
7.4 BIOPSIES 112
TABLE 53 CANCER DIAGNOSTICS MARKET FOR BIOPSIES, BY REGION,
2019–2026 (USD MILLION) 113
8 CANCER DIAGNOSTICS MARKET, BY APPLICATION 114
8.1 INTRODUCTION 115
TABLE 54 CANCER DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 115

8.2 BREAST CANCER 115
8.2.1 BREAST CANCER SEGMENT TO ACCOUNT FOR THE LARGEST SHARE DURING THE FORECAST PERIOD 115
TABLE 55 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040 115
TABLE 56 CANCER DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION,
2019–2026 (USD MILLION) 116
8.3 LUNG CANCER 116
8.3.1 LUNG CANCER SEGMENT ACCOUNTED FOR THE SECOND-
LARGEST SHARE IN 2020 116
TABLE 57 LUNG CANCER INCIDENCE, BY REGION, 2020 VS. 2040 116
TABLE 58 CANCER DIAGNOSTICS MARKET FOR LUNG CANCER, BY REGION,
2019–2026 (USD MILLION) 117
8.4 COLORECTAL CANCER 117
8.4.1 INCREASING INCIDENCE OF COLORECTAL CANCER TO
DRIVE MARKET GROWTH 117
TABLE 59 COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS. 2040 117
TABLE 60 CANCER DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2019–2026 (USD MILLION) 118
8.5 MELANOMA 118
8.5.1 INCREASING INCIDENCE OF MELANOMA TO DRIVE MARKET GROWTH 118
TABLE 61 MELANOMA INCIDENCE, BY REGION, 2020 VS. 2040 118
TABLE 62 CANCER DIAGNOSTICS MARKET FOR MELANOMA, BY REGION,
2019–2026 (USD MILLION) 119
8.6 OTHER CANCERS 119
TABLE 63 CANCER DIAGNOSTICS MARKET FOR OTHER CANCERS, BY REGION,
2019–2026 (USD MILLION) 120
9 CANCER DIAGNOSTICS MARKET, BY END USER 121
9.1 INTRODUCTION 122
TABLE 64 CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION) 122
9.2 HOSPITALS 122
9.2.1 HOSPITALS ARE THE LARGEST END USERS OF
CANCER DIAGNOSTIC PRODUCTS 122
TABLE 65 CANCER DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION,
2019–2026 (USD MILLION) 123
9.3 DIAGNOSTIC LABORATORIES 123
9.3.1 INCREASING INCIDENCE OF CANCER TO DRIVE THE GROWTH OF
THIS SEGMENT 123
TABLE 66 CANCER DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES,
BY REGION, 2019–2026 (USD MILLION) 123
10 CANCER DIAGNOSTICS MARKET, BY REGION 124
10.1 INTRODUCTION 125
TABLE 67 CANCER DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION) 125
10.2 NORTH AMERICA 125
FIGURE 24 NORTH AMERICA: CANCER DIAGNOSTICS MARKET SNAPSHOT 126
TABLE 68 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 126
TABLE 69 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 127
TABLE 70 NORTH AMERICA: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES,
BY TYPE, 2019–2026 (USD MILLION) 127
TABLE 71 NORTH AMERICA: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS,
BY TYPE, 2019–2026 (USD MILLION) 127
TABLE 72 NORTH AMERICA: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 128
TABLE 73 NORTH AMERICA: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 128
TABLE 74 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 128
TABLE 75 NORTH AMERICA: CANCER DIAGNOSTICS MARKET FOR IVD TESTING,
BY TYPE, 2019–2026 (USD MILLION) 129
TABLE 76 NORTH AMERICA: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION) 129
TABLE 77 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 130
TABLE 78 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 130
10.2.1 US 130
10.2.1.1 US is expected to be dominant in the North American market 130
TABLE 79 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 131
TABLE 80 US: CANCER DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 131
TABLE 81 US: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2019–2026 (USD MILLION) 132
TABLE 82 US: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE,
2019–2026 (USD MILLION) 132
TABLE 83 US: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 132
TABLE 84 US: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 133
TABLE 85 US: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 133
TABLE 86 US: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE,
2019–2026 (USD MILLION) 133
TABLE 87 US: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION) 134
TABLE 88 US: CANCER DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 134
TABLE 89 US: CANCER DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 134
10.2.2 CANADA 135
10.2.2.1 High prevalence of cancer in Canada is expected to
support market growth 135
TABLE 90 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 135
TABLE 91 CANADA: CANCER DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 136
TABLE 92 CANADA: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION) 136
TABLE 93 CANADA: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 136
TABLE 94 CANADA: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 137
TABLE 95 CANADA: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS,
BY TYPE, 2019–2026 (USD MILLION) 137
TABLE 96 CANADA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 137
TABLE 97 CANADA: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE,
2019–2026 (USD MILLION) 138
TABLE 98 CANADA: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES,
BY TYPE, 2019–2026 (USD MILLION) 138
TABLE 99 CANADA: CANCER DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 139
TABLE 100 CANADA: CANCER DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 139
10.3 EUROPE 139
TABLE 101 EUROPE: CANCER DIAGNOSTICS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 140
TABLE 102 EUROPE: CANCER DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 140
TABLE 103 EUROPE: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION) 140
TABLE 104 EUROPE: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 141
TABLE 105 EUROPE: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 141
TABLE 106 EUROPE: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS,
BY TYPE, 2019–2026 (USD MILLION) 141
TABLE 107 EUROPE: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 142
TABLE 108 EUROPE: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE,
2019–2026 (USD MILLION) 142
TABLE 109 EUROPE: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES,
BY TYPE, 2019–2026 (USD MILLION) 142
TABLE 110 EUROPE: CANCER DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 143
TABLE 111 EUROPE: CANCER DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 143
10.3.1 GERMANY 144
10.3.1.1 Availability of reimbursements for colorectal cancer screening to drive market growth 144
TABLE 112 GERMANY: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 144
TABLE 113 GERMANY: CANCER DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 145
TABLE 114 GERMANY: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION) 145
TABLE 115 GERMANY: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 145
TABLE 116 GERMANY: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 146
TABLE 117 GERMANY: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS,
BY TYPE, 2019–2026 (USD MILLION) 146
TABLE 118 GERMANY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 146
TABLE 119 GERMANY: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION) 147
TABLE 120 GERMANY: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION) 147
TABLE 121 GERMANY: CANCER DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 148
TABLE 122 GERMANY: CANCER DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 148
10.3.2 UK 148
10.3.2.1 Government initiatives to drive market growth in the UK 148
TABLE 123 UK: CANCER DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 149
TABLE 124 UK: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2019–2026 (USD MILLION) 149
TABLE 125 UK: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE,
2019–2026 (USD MILLION) 150
TABLE 126 UK: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 150
TABLE 127 UK: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 150
TABLE 128 UK: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 151
TABLE 129 UK: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE,
2019–2026 (USD MILLION) 151
TABLE 130 UK: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION) 151
TABLE 131 UK: CANCER DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 152
TABLE 132 UK: CANCER DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 152
10.3.3 FRANCE 152
10.3.3.1 Increasing government funding for cancer diagnosis and prevention to support the market growth 152
TABLE 133 FRANCE: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 153
TABLE 134 FRANCE: CANCER DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 153
TABLE 135 FRANCE: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION) 154
TABLE 136 FRANCE: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 154
TABLE 137 FRANCE: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 154
TABLE 138 FRANCE: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS,
BY TYPE, 2019–2026 (USD MILLION) 155
TABLE 139 FRANCE: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 155
TABLE 140 FRANCE: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE,
2019–2026 (USD MILLION) 155
TABLE 141 FRANCE: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES,
BY TYPE, 2019–2026 (USD MILLION) 156
TABLE 142 FRANCE: CANCER DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 156
TABLE 143 FRANCE: CANCER DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 156
10.3.4 ITALY 157
10.3.4.1 High incidence of cancer to support the market growth in Italy 157
TABLE 144 ITALY: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 157
TABLE 145 ITALY: CANCER DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 158
TABLE 146 ITALY: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2019–2026 (USD MILLION) 158
TABLE 147 ITALY: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE,
2019–2026 (USD MILLION) 158
TABLE 148 ITALY: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 159
TABLE 149 ITALY: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS,
BY TYPE, 2019–2026 (USD MILLION) 159
TABLE 150 ITALY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 159
TABLE 151 ITALY: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE,
2019–2026 (USD MILLION) 160
TABLE 152 ITALY: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES,
BY TYPE, 2019–2026 (USD MILLION) 160
TABLE 153 ITALY: CANCER DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 161
TABLE 154 ITALY: CANCER DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 161
10.3.5 SPAIN 161
10.3.5.1 High incidence of chronic diseases to drive the market
growth in Spain 161
TABLE 155 SPAIN: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 161
TABLE 156 SPAIN: CANCER DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 162
TABLE 157 SPAIN: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION) 162
TABLE 158 SPAIN: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE,
2019–2026 (USD MILLION) 163
TABLE 159 SPAIN: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 163
TABLE 160 SPAIN: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS,
BY TYPE, 2019–2026 (USD MILLION) 163
TABLE 161 SPAIN: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 164
TABLE 162 SPAIN: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE,
2019–2026 (USD MILLION) 164
TABLE 163 SPAIN: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES,
BY TYPE, 2019–2026 (USD MILLION) 164
TABLE 164 SPAIN: CANCER DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 165
TABLE 165 SPAIN: CANCER DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 165
10.3.6 REST OF EUROPE 165
TABLE 166 LUNG CANCER INCIDENCE IN KEY ROE COUNTRIES, 2018 VS. 2025 165
TABLE 167 LIVER CANCER INCIDENCE IN KEY ROE COUNTRIES, 2018 VS. 2025 166
TABLE 168 BREAST CANCER INCIDENCE IN KEY ROE COUNTRIES, 2018 VS. 2025 166
TABLE 169 ROE: CANCER DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 167
TABLE 170 ROE: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2019–2026 (USD MILLION) 167
TABLE 171 ROE: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE,
2019–2026 (USD MILLION) 167
TABLE 172 ROE: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 168
TABLE 173 ROE: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 168
TABLE 174 ROE: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 168
TABLE 175 ROE: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE,
2019–2026 (USD MILLION) 169
TABLE 176 ROE: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES,
BY TYPE, 2019–2026 (USD MILLION) 169
TABLE 177 ROE: CANCER DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 170
TABLE 178 ROE: CANCER DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 170
10.4 ASIA PACIFIC 170
FIGURE 25 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET SNAPSHOT 171
TABLE 179 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 171
TABLE 180 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 172
TABLE 181 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES,
BY TYPE, 2019–2026 (USD MILLION) 172
TABLE 182 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 172
TABLE 183 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-
BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 173
TABLE 184 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 173
TABLE 185 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 173
TABLE 186 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION) 174
TABLE 187 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION) 174
TABLE 188 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 175
TABLE 189 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 175

10.4.1 CHINA 176
10.4.1.1 Increasing healthcare expenditure to drive market growth in China 176
TABLE 190 CHINA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 176
TABLE 191 CHINA: CANCER DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 176
TABLE 192 CHINA: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION) 177
TABLE 193 CHINA: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE,
2019–2026 (USD MILLION) 177
TABLE 194 CHINA: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 177
TABLE 195 CHINA: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS,
BY TYPE, 2019–2026 (USD MILLION) 178
TABLE 196 CHINA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 178
TABLE 197 CHINA: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE,
2019–2026 (USD MILLION) 178
TABLE 198 CHINA: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES,
BY TYPE, 2019–2026 (USD MILLION) 179
TABLE 199 CHINA: CANCER DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 179
TABLE 200 CHINA: CANCER DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 179
10.4.2 JAPAN 180
10.4.2.1 Advanced healthcare infrastructure to support market
growth in Japan 180
TABLE 201 JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 180
TABLE 202 JAPAN: CANCER DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 180
TABLE 203 JAPAN: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION) 181
TABLE 204 JAPAN: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE,
2019–2026 (USD MILLION) 181
TABLE 205 JAPAN: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 181
TABLE 206 JAPAN: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS,
BY TYPE, 2019–2026 (USD MILLION) 182
TABLE 207 JAPAN: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 182
TABLE 208 JAPAN: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE,
2019–2026 (USD MILLION) 182
TABLE 209 JAPAN: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES,
BY TYPE, 2019–2026 (USD MILLION) 183
TABLE 210 JAPAN: CANCER DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 183
TABLE 211 JAPAN: CANCER DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 183
10.4.3 INDIA 184
10.4.3.1 Expanding healthcare sector in the country to drive market growth 184
TABLE 212 INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 184
TABLE 213 INDIA: CANCER DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 184
TABLE 214 INDIA: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2019–2026 (USD MILLION) 185
TABLE 215 INDIA: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE,
2019–2026 (USD MILLION) 185
TABLE 216 INDIA: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 185
TABLE 217 INDIA: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS,
BY TYPE, 2019–2026 (USD MILLION) 186
TABLE 218 INDIA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 186
TABLE 219 INDIA: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE,
2019–2026 (USD MILLION) 186
TABLE 220 INDIA: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES,
BY TYPE, 2019–2026 (USD MILLION) 187
TABLE 221 INDIA: CANCER DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 187
TABLE 222 INDIA: CANCER DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 187
10.4.4 REST OF ASIA PACIFIC 188
TABLE 223 INCIDENCE OF CANCER IN ROAPAC COUNTRIES 188
TABLE 224 ROAPAC: CANCER DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 188
TABLE 225 ROAPAC: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION) 189
TABLE 226 ROAPAC: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 189
TABLE 227 ROAPAC: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 189
TABLE 228 ROAPAC: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS,
BY TYPE, 2019–2026 (USD MILLION) 190
TABLE 229 ROAPAC: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 190
TABLE 230 ROAPAC: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE,
2019–2026 (USD MILLION) 190
TABLE 231 ROAPAC: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES,
BY TYPE, 2019–2026 (USD MILLION) 191
TABLE 232 ROAPAC: CANCER DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 191
TABLE 233 ROAPAC: CANCER DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 191
10.5 REST OF THE WORLD 192
TABLE 234 ROW: CANCER DIAGNOSTICS MARKET, BY REGION,
2019–2026 (USD MILLION) 192
TABLE 235 ROW: CANCER DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 192
TABLE 236 ROW: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2019–2026 (USD MILLION) 192
TABLE 237 ROW: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE,
2019–2026 (USD MILLION) 193
TABLE 238 ROW: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 193
TABLE 239 ROW: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS,
BY TYPE, 2019–2026 (USD MILLION) 193
TABLE 240 ROW: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 194
TABLE 241 ROW: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE,
2019–2026 (USD MILLION) 194
TABLE 242 ROW: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES,
BY TYPE, 2019–2026 (USD MILLION) 194
TABLE 243 ROW: CANCER DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 195
TABLE 244 ROW: CANCER DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 195
10.5.1 LATIN AMERICA 195
10.5.1.1 Increasing number of cancer screening programs to
support market growth 195
TABLE 245 LUNG CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES,
2018 VS. 2025 196
TABLE 246 LIVER CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES,
2018 VS. 2025 196
TABLE 247 BREAST CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES,
2018 VS. 2025 196
TABLE 248 LATIN AMERICA: CANCER DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 197
TABLE 249 LATIN AMERICA: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES,
BY TYPE, 2019–2026 (USD MILLION) 197
TABLE 250 LATIN AMERICA: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS,
BY TYPE, 2019–2026 (USD MILLION) 198
TABLE 251 LATIN AMERICA: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-
BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 198
TABLE 252 LATIN AMERICA: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 198
TABLE 253 LATIN AMERICA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 199
TABLE 254 LATIN AMERICA: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION) 199
TABLE 255 LATIN AMERICA: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION) 199
TABLE 256 LATIN AMERICA: CANCER DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 200
TABLE 257 LATIN AMERICA: CANCER DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 200
10.5.2 MIDDLE EAST & AFRICA 200
10.5.2.1 Increasing incidence of cancer in the Middle East & Africa to
drive market growth 200
TABLE 258 AFRICA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 201
TABLE 259 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 201
TABLE 260 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION) 202
TABLE 261 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 202
TABLE 262 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 202
TABLE 263 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION) 203
TABLE 264 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 203
TABLE 265 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION) 204
TABLE 266 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION) 204
TABLE 267 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 205
TABLE 268 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION) 205
11 COMPETITIVE LANDSCAPE 206
11.1 OVERVIEW 206
FIGURE 26 KEY DEVELOPMENTS IN THE CANCER DIAGNOSTICS MARKET,
JANUARY 2018–APRIL 2021 206
FIGURE 27 MARKET EVOLUTION MATRIX: JANUARY 2018 TO APRIL 2021 207
11.2 MARKET SHARE ANALYSIS 207
TABLE 269 CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES:
DEGREE OF COMPETITION 207
TABLE 270 CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS: DEGREE OF COMPETITION 208
TABLE 271 CANCER DIAGNOSTICS MARKET FOR BIOPSY INSTRUMENTS:
DEGREE OF COMPETITION 209
11.3 COMPANY EVALUATION MATRIX 209
11.3.1 STARS 209
11.3.2 EMERGING LEADERS 209
11.3.3 PERVASIVE PLAYERS 209
11.3.4 PARTICIPANTS 209
FIGURE 28 VENDOR DIVE: CANCER DIAGNOSTICS MARKET 210
11.4 COMPETITIVE LEADERSHIP MAPPING (SMES/ START-UPS) 211
11.4.1 PROGRESSIVE COMPANIES 211
11.4.2 STARTING BLOCKS 211
11.4.3 RESPONSIVE COMPANIES 211
11.4.4 DYNAMIC COMPANIES 211
FIGURE 29 VENDOR DIVE MATRIX FOR SMES & START-UPS:
CANCER DIAGNOSTICS MARKET 212
11.5 COMPETITIVE SCENARIO 213
11.5.1 PRODUCT LAUNCHES & APPROVALS 213
TABLE 272 KEY PRODUCT LAUNCHES & APPROVALS, JANUARY 2018–APRIL 2021 213
11.5.2 DEALS 214
TABLE 273 KEY DEALS, JANUARY 2018–APRIL 2021 214
11.5.3 OTHER DEVELOPMENTS 215
TABLE 274 OTHER KEY DEVELOPMENTS, JANUARY 2018–APRIL 2021 215
11.5.4 COMPANY FOOTPRINT 216
TABLE 275 COMPANY FOOTPRINT 216
TABLE 276 COMPANY PRODUCT FOOTPRINT 217
TABLE 277 COMPANY APPLICATION FOOTPRINT 218
TABLE 278 COMPANY GEOGRAPHICAL FOOTPRINT 219
12 COMPANY PROFILES 220
12.1 KEY PLAYERS 220
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, and Right to Win)*
12.1.1 GE HEALTHCARE 220
TABLE 279 GE HEALTHCARE: BUSINESS OVERVIEW 220
FIGURE 30 GE HEALTHCARE: COMPANY SNAPSHOT (2020) 221
12.1.2 BECTON, DICKINSON AND COMPANY 225
TABLE 280 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 225
FIGURE 31 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020) 225
12.1.3 ROCHE DIAGNOSTICS 229
TABLE 281 F. HOFFMAN-LA ROCHE LTD.: BUSINESS OVERVIEW 229
FIGURE 32 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020) 230
12.1.4 DANAHER CORPORATION 235
TABLE 282 DANAHER CORPORATION: BUSINESS OVERVIEW 235
FIGURE 33 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 235
12.1.5 THERMO FISHER SCIENTIFIC 239
TABLE 283 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW 239
FIGURE 34 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020) 239
12.1.6 ABBOTT LABORATORIES 243
TABLE 284 ABBOTT LABORATORIES: BUSINESS OVERVIEW 243
FIGURE 35 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020) 243
12.1.7 QIAGEN N.V. 245
TABLE 285 QIAGEN N.V.: BUSINESS OVERVIEW 245
FIGURE 36 QIAGEN N.V.: COMPANY SNAPSHOT (2020) 245
12.1.8 AGILENT TECHNOLOGIES INC. 248
TABLE 286 AGILENT TECHNOLOGIES INC.: BUSINESS OVERVIEW 248
FIGURE 37 AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT (2020) 248
12.1.9 ILLUMINA, INC. 251
TABLE 287 ILLUMINA INC.: BUSINESS OVERVIEW 251
FIGURE 38 ILLUMINA, INC.: COMPANY SNAPSHOT (2020) 251
12.1.10 SIEMENS HEALTHINEERS AG 254
TABLE 288 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW 254
FIGURE 39 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2020) 254
12.1.11 DIASORIN S.P.A. 257
TABLE 289 DIASORIN S.P.A.: BUSINESS OVERVIEW 257
FIGURE 40 DIASORIN S.P.A.: COMPANY SNAPSHOT (2019) 258
12.1.12 MYRIAD GENETICS INC. 259
TABLE 290 MYRIAD GENETICS INC.: BUSINESS OVERVIEW 259
FIGURE 41 MYRIAD GENETICS INC.: COMPANY SNAPSHOT (2020) 259
12.1.13 HOLOGIC, INC. 262
TABLE 291 HOLOGIC, INC.: BUSINESS OVERVIEW 262
FIGURE 42 HOLOGIC INC.: COMPANY SNAPSHOT (2020) 262
12.1.14 BIOMÉRIEUX SA 264
TABLE 292 BIOMÉRIEUX SA: BUSINESS OVERVIEW 264
FIGURE 43 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2020) 265
12.1.15 FUJIFILM HOLDINGS CORPORATION 266
TABLE 293 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW 266
FIGURE 44 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2020) 267
12.2 START-UP/SME PLAYERS 269
12.2.1 QUIDEL CORPORATION 269
TABLE 294 QUIDEL CORPORATION: BUSINESS OVERVIEW 269
FIGURE 45 QUIDEL CORPORATION: COMPANY SNAPSHOT (2020) 270
12.2.2 EXACT SCIENCES 271
TABLE 295 EXACT SCIENCES: BUSINESS OVERVIEW 271
FIGURE 46 EXACT SCIENCES: COMPANY SNAPSHOT (2020) 271
12.2.3 BIOCARTIS NV 274
TABLE 296 BIOCARTIS NV: BUSINESS OVERVIEW 274
FIGURE 47 BIOCARTIS NV: COMPANY SNAPSHOT (2020) 274
12.2.4 CANCER DIAGNOSTICS INC. 276
TABLE 297 CANCER DIAGNOSTICS INC.: BUSINESS OVERVIEW 276
12.2.5 AMOY DIAGNOSTICS CO. LTD. 277
TABLE 298 AMOY DIAGNOSTICS CO. LTD.: BUSINESS OVERVIEW 277
12.2.6 BIO-RAD LABORATORIES 280
TABLE 299 BIO-RAD LABORATORIES: BUSINESS OVERVIEW 280
FIGURE 48 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2020) 281
12.2.7 BIO SB 282
TABLE 300 BIO SB: BUSINESS OVERVIEW 282
12.2.8 VELA DIAGNOSTICS 283
TABLE 301 VELA DIAGNOSTICS: BUSINESS OVERVIEW 283
* Business Overview, Products Offered, Recent Developments, SWOT Analysis, and Right to Win might not be captured in case of unlisted companies.
13 APPENDIX 284
13.1 DISCUSSION GUIDE 284
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 289
13.3 AVAILABLE CUSTOMIZATIONS 291
13.4 RELATED REPORTS 292
13.5 AUTHOR DETAILS 293

★調査レポート[世界のがん診断市場予測(~2026年):製品別(消耗品(抗体、プローブ)、器具(病理学器具、画像用器具、生検)、技術別(IVD検査)、用途別(乳がん、肺がん)、エンドユーザー別(病院)] (コード:MD3480)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のがん診断市場予測(~2026年):製品別(消耗品(抗体、プローブ)、器具(病理学器具、画像用器具、生検)、技術別(IVD検査)、用途別(乳がん、肺がん)、エンドユーザー別(病院)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆